Direct Medical Spending on Young and Average-Age Onset Colorectal Cancer before and after Diagnosis: a Population-Based Costing Study
Ria Garg(St. Michael's Hospital), Mary A. De Vera, Helen McTaggart‐Cowan(Fraser Health), Eric C. Sayre(Research Canada), Jonathan M. Loree(University of British Columbia), Stuart Peacock(BC Cancer Agency), Reka Pataky(BC Cancer Agency), Carl J. Brown(University of British Columbia), Michael McKenzie(Provincial Health Services Authority), Shirley S.T. Yeung(BC Cancer Agency)
Cited by 7
Related Papers
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
|International Journal of Radiation Oncology*Biology*Physics|2016|736
Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018
|JAMA Oncology|2019|568
Volumetric Modulated Arc Therapy for Delivery of Prostate Radiotherapy: Comparison With Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy
|International Journal of Radiation Oncology*Biology*Physics|2008|532
ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer
|International Journal of Radiation Oncology*Biology*Physics|2017|319